PARP1 and neoplasm: In this regard, it is notable that inhibiting PARP or CHK1 in the presence of anti-PD-L1 antibodies caused tumor regression in SCLC mouse models, which was accompanied by CD8+ T-cell infiltration (Sen et al. 2019b).